Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1148

Endostatin Peptides with Anti-Tumor Properties

Inventors: M. Folkman, Kashi Javaherian, Robert Tjin Tham Sjin

Invention Types: Therapeutics

Research Areas: Oncology/Hematology

Keywords: Anti-angiogenesis, Composition of Matter, Peptide, Gene Therapy

Related Cases: 474, 1318

For More Information Contact:  Dietz, Ryan

 

Invention Description:

Endostatin is a cleavage fragment from the C-terminal domain of collagen XVIII (see CMCC technology # 474) that has been developed as a clinical therapeutic, reaching phase II clinical trials with a very favorable safety profile. Endostatin and has been found to possess anti-angiogenic properties, including inhibition of endothelial cell proliferation, migration, and tube formation, as well as VEGF induced vascular permeability.

|Investigators at Children's Hospital Boston have identified a novel 27 amino acid fragment at the N terminus of endostatin that has anti-tumor, anto-angiogenic and anti-endothelial cell proliferation activity comparable to that of the full length protein. The peptide could be used as a therapeutic or the nucleic acid sequence that encodes it could be used as a gene therapy agent. The peptides have also been demonstrated to have activity against endometriosis (see CMCC technology # 1318).

Applications:

Anti-angiogenesis|Oncology|Solid Tumor

Competitive Advantages:

The short synthetic endostatin peptides described here would be easier and cheaper to manufacture than the original form of endostatin, while anticipated to have a similar favorable safety and efficacy profile. The peptides represent new composition of matter with patents allowed as of early 2009 in the US and Europe.

Business Opportunity:

Exclusive License|Start-up

Key Publications: A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity.
||Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VM, Folkman J, Javaherian K.

||Cancer Res. 2005 May 1;65(9):3656-63.

||US Patent application 11/364,855 (allowed) and EPO patent application 04782583.1 (allowed)

Related Publications: Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model.
|Becker CM, Sampson DA, Short SM, Javaherian K, Folkman J, D'Amato RJ.

||Fertil Steril. 2006 Jan;85(1):71-7.

IPStatus: Patented